Regencell Bioscience Holdings Limited
RGC
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine-based products. Regencell Bioscience Holdings Limited concentrates on treatments for neurocognitive disorders and degeneration, with particular attention to attention deficit hyperactivity disorder and autism spectrum disorder. The company also applies its bioscience platform to infectious diseases that affect the immune system, reflecting a broader therapeutic scope within natural and holistic healthcare. Its product development approach centers on standardized TCM formulations designed for clinical use, positioning the company within the specialty biopharmaceutical segment of the health technology market. Regencell Bioscience Holdings Limited serves as a niche participant in the medical and pharmaceutical landscape by targeting conditions with unmet treatment needs through non-conventional medicine-based research and commercialization.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$4M
▲ +28.0% YoY
Op. Margin
–
ROIC
-36.05%
▼ -3.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▲ +19.7% YoY
Op. Cash Flow (TTM)
-$4M
▲ +19.0% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with RGC
Held by ETFs
RGC is in 3 US ETFs. The largest of them, with RGC's weight in each:
Regencell Bioscience Holdings (RGC) in three numbers
Questions about Regencell Bioscience Holdings
Is Regencell Bioscience Holdings a high-quality business?
Regencell Bioscience Holdings scores 16 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$8M, and its weakest is return on capital at -36.1%. The Quality tab shows every check against its target.
Does Regencell Bioscience Holdings (RGC) pay a dividend?
No. Regencell Bioscience Holdings (RGC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RGC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.